Current Report Filing (8-k)
March 05 2018 - 6:16AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of report (date of earliest event reported): March 5, 2018
OWC
Pharmaceutical Research Corp.
(Exact Name of Registrant as Specified in its Charter)
Commission
File No.: 0-54856
Delaware
|
|
98-0573566
|
(State
of
Incorporation)
|
|
(I.R.S.
Employer
Identification
No.)
|
|
|
|
2
Ben Gurion Street, Ramat Gan, Israel
|
|
4514760
|
(Address
of Principal Executive Offices)
|
|
(Zip
Code)
|
Registrant’s
Telephone Number, including area code: 972 (0) 3-758-2657
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2. below):
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item
8.01. Other Events.
OWC
Pharmaceutical Research Corp. (the “Registrant”), is filing with this Form 8-K, a link to a video interview of Dr.
Stanley Hirsch, Chairman of the Registrant’s Board of Directors, conducted by Mike Elliott of CEOlive at the 2018 Wall Street
Conference held in Deerfield Beach, FL on February 21, 2018. The link to the video conference referenced in Exhibit 99.1 hereto,
is:
https://www.youtube.com/watch?v=VkW7_56ZSv0&feature=youtu.be
For information regarding the Registrant and
to view its news and video releases including the interview of Dr. Hirsch, please visit the Registrant’s website at:
http://www.owcpharma.com/newsroom-photos/
Item
9.01 Financial Statements and Exhibits.
(a) The following documents are filed as exhibits to this report on Form 8-K or incorporated by reference
herein. Any document incorporated by reference is identified by a parenthetical reference to the SEC filing that included such
document.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
OWC
Pharmaceutical Research Corp.
|
|
|
|
|
By:
|
/s/
Mordechai Bignitz
|
|
Name:
|
Mordechai
Bignitz
|
|
Title:
|
Chief
Executive Officer
|
|
Date:
March 5, 2018
OWC Pharmaceuticals Rese... (CE) (USOTC:OWCP)
Historical Stock Chart
From Aug 2024 to Sep 2024
OWC Pharmaceuticals Rese... (CE) (USOTC:OWCP)
Historical Stock Chart
From Sep 2023 to Sep 2024